Is this email not displaying correctly? View it in your browser.
 
Newswise - News for Journalists
Newswise Special Wire
Monday, August 1, 2016

Public edition | newswise.com

Newswise Cancer Research Wire for 01-Aug-2016
 

Cancer Research Wire

Cancer research news for the public and news media. More stories can be found at the Newswise Cancer News Source.



Cancer-Fighting Therapy Shows Promise as Treatment to Speed Up Wound Healing, UCLA Study Finds

A type of targeted therapy that has shown promising results treating advanced melanoma could also be used to help speed up how the skin repairs itself from injury, UCLA researchers have found, providing a potential new way to accelerate healing of acute and chronic wounds.

– University of California, Los Angeles (UCLA), Health Sciences

Nature Communications

Embargo expired on 01-Aug-2016 at 05:00 ET


One of the Most Common Viruses in Humans May Promote Breast Cancer Development

New research reveals that infection with the Epstein–Barr virus (EBV) may put some women at increased risk for developing breast cancer. The findings, published online in the July issue of the journal EBioMedicine, may have important implications for breast cancer screening and prevention.

– Beth Israel Deaconess Medical Center

EBioMedicine; R01AI063571 (JDF); CA019014; DE018304 (DPD)


New Study Finds CD4 T-Cell and Blimp-1 Protein Critical to Toxoplasmosis Regulation

Researchers from the George Washington University published in the Journal of Experimental Medicine finding a way to regulate chronic toxoplasmosis, one of the most common parasitic diseases worldwide.

– George Washington University


Social Media Linked to More Satisfaction with Breast Cancer Treatment Decisions

Women who engaged on social media after a breast cancer diagnosis expressed more deliberation about their treatment decision and more satisfaction with the path they chose, a new study finds.

– University of Michigan Health System

JAMA Oncology; CA163233

Embargo expired on 28-Jul-2016 at 11:00 ET


Protein ZMYND8 Tied to Suppression of Prostate Cancer Tumor Metastasis

Although it reads like European license plate number, a protein known as ZMYND8 has demonstrated its ability to block metastasis-linked genes in prostate cancer, according to a study at The University of Texas MD Anderson Cancer Center.

– University of Texas M. D. Anderson Cancer Center

Embargo expired on 28-Jul-2016 at 12:00 ET


Study Shows Poor Skin Cancer Survival in Patients with Skin of Color

Because Caucasians have a higher skin cancer risk than the general population, people with skin of color may believe that they don’t need to be concerned about this disease — but new research reveals this to be a dangerous misconception.

– American Academy of Dermatology

Journal of the American Academy of Dermatology


Early Detection of Leukemia Patients' Resistance to Therapy

Australian researchers have made a world-first breakthrough in the early detection of patients' resistance to a common treatment for chronic myeloid leukemia.

– University of Adelaide

Leukemia


T-Cells Can Be Directed to Treat a Variety of Ovarian Cancers

Scientists at The Wistar Institute have discovered a receptor-protein that is expressed on the surface of different types of ovarian tumor cells, including clear cell and mucinous ovarian tumors, two of the most aggressive subtypes of the disease. The protein is not found on non-ovarian healthy tissues in adult women, meaning that this protein could represent a highly specific therapeutic target in a range of ovarian tumors. Additionally, T-cells could be directed to treat these tumors with almost no adverse effects observed.

– Wistar Institute

Clinical Cancer Research, July-2015


Scientists Discover New Therapeutic Target for Lung Cancer Driven by KRAS

UT Southwestern Medical Center researchers have identified a new way to target lung cancer through the KRAS gene, one of the most commonly mutated genes in human cancer and one researchers have so far had difficulty targeting successfully.

– UT Southwestern Medical Center

Cell Reports, 2016


Roswell Park Findings Will Help Clinicians Select Best Therapy for Patients with Advanced Liver Cancer

New research from Roswell Park Cancer Institute offers clinicians treating patients with advanced liver cancer a way of determining which patients may benefit most from the targeted therapy sorafenib.

– Roswell Park Cancer Institute


Hybrid Treatment Hunts Down and Kills Leukemia Cells

Researchers at UC Davis and Ionis Pharmaceuticals have developed a hybrid treatment that harnesses a monoclonal antibody to deliver antisense DNA to acute lymphoblastic leukemia (ALL) cells and that may lead to less toxic treatments for the disease.

– UC Davis Comprehensive Cancer Center

National Institutes of Health (grants UL1 418 TR000002, R01GM099688, CTSC-MCRTP


Insurance and Distance to Care Can Be Barriers to Breast Reconstruction

Researchers say breast reconstruction can help with self-esteem, sexuality and body image after mastectomy. But a University of North Carolina Lineberger Comprehensive Cancer Center study has found that the type of insurance a woman has as well as distance to a plastic surgeon's office can be barriers to the procedure.

– University of North Carolina Health Care System

Plastic and Reconstructive Surgery, July-2016


NUS Study Uncovers Novel Genetic Alterations Contributing to Development of Leukemia

A study led by a team of scientists from the Cancer Science Institute of Singapore at the National University of Singapore has identified new genetic alterations contributing to the onset of Acute Promyelocytic Leukemia (APL). APL is a subtype of Acute Myeloid Leukemia, where there is an abnormal accumulation of immature white blood cells called promyelocytes.

– National University of Singapore

Leukemia


First Cancer Patient in Ohio Receives Proton Therapy Treatment

University Hospitals in Cleveland treated its first patient using the MEVION S250 proton therapy system. The proton therapy treatment was the first in the State of Ohio.

– University Hospitals Case Medical Center


Updated Testing Guidelines Make More Women Eligible for Herceptin, Yet Benefit Uncertain

ROCHESTER, Minn. — Changes to HER2 testing guidelines for breast cancer in 2013 significantly increased the number of patients who test HER2-positive, according to a new study by Mayo Clinic researchers published in the Journal of Clinical Oncology. Cancers that have an excess of HER2 protein or extra copies of the HER2 gene are called HER2-positive and can be treated with drugs like Herceptin that target HER2. HER2 stands for human epidermal growth factor receptor 2.

– Mayo Clinic

Journal of Clinical Oncology


Tiny 3-D Models May Yield Big Insights Into Ovarian Cancer

With a unique approach that draws on 3-D printing technologies, a team of University of Wisconsin–Madison researchers is developing new tools for understanding how ovarian cancer develops in women.

– University of Wisconsin-Madison


Researchers ID Cancer Gene-Drug Combinations Ripe for Precision Medicine; Many Skin Cancer Patients Still Too Likely to Sunburn; Researchers Block Common Type of Colon Cancer Tumor in Mice, and More in the Cancer News Source

Personalized Medicine Leads to Better Outcomes; Phase 1 Study Results of Selinexor Combination Therapy for Multiple Myeloma Patients; and the Latest from ASCO Sessions in the Cancer News Source

– Newswise


International Study Finds Effective, Less Toxic Way to Treat Brain Tumors

/PRNewswire-USNewswire/ -- Physicians from Carolinas HealthCare System's Neurosciences Institute and Levine Cancer Institute are among the authors of a study that was accepted for publication by the Journal of the American Medical Association (JAMA). The study, released on July 26, 2016, shows that patients with the most common form of brain tumor can be treated in an effective and substantially less toxic way by omitting a widely used portion of radiation therapy. These results will allow tens of thousands of patients with brain tumors to experience a better quality of life while maintaining the same length of life.

– Carolinas Healthcare System

Journal of the American Medical Association


Genetic Profiling Increases Cancer Treatment Options, Sanford Study Finds

GEMMA clinical trial identified treatment options through personalized medicine

– Sanford Health

ASCO Annual Meeting, July 2016


Cord Blood Outperforms Matched, Unrelated Donor in Bone Marrow Transplant

A University of Colorado Cancer Center study finds that three years post bone marrow transplant, the incidence of severe chronic graft-versus-host disease was 44 percent in patients who had received transplants from matched, unrelated donors (MUD) and 8 percent in patients who had received umbilical cord blood transplants (CBT).

– University of Colorado Cancer Center

Bone Marrow Transplantation


Stereotactic Radiosurgery May Be Best for Patients with Metastatic Brain Tumors

ROCHESTER, Minn. — Patients with three or fewer metastatic brain tumors who received treatment with stereotactic radiosurgery (SRS) had less cognitive deterioration three months after treatment than patients who received SRS combined with whole brain radiation therapy (WBRT). These findings are according to the results of a federally funded, Mayo Clinic-led, multi-institution research study published today in the Journal of the American Medical Association.

– Mayo Clinic


Increasing the Odds of Prostate Cancer Detection

VCU Health radiologist Jinxing Yu, M.D., uses magnetic resonance technology to diagnose with more than 90 percent success rate.

– VCU Massey Cancer Center


Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer

A laboratory study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes. The findings, reported by Andre Nussenzweig, Ph.D., and Shyam Sharan, Ph.D., at the National Cancer Institute (NCI), part of the National Institutes of Health, and colleagues, appeared July 21, 2016, in Nature.

– National Cancer Institute (NCI) at NIH

Nature, July 21, 2016. DOI: 10.1038/nature18325.


Policy and Public Affairs


Raising Tobacco Sales Age to 21 Is Best Way to Prevent Lifelong Addiction

COLUMBUS, Ohio – Raising the national minimum age to buy cigarettes to 21 would save lives by preventing adolescents from ever taking up smoking, a new report suggests. The minimum age to buy tobacco products in most of the country is 18. In their analysis, Ohio State University public health experts detail how raising the minimum tobacco sales age would be effective in improving health and note the economic consequences to retailers would be minimal.

– Ohio State University


Announcements


Five New Studies Will Examine How the Trillions of Tiny Organisms That Call Our Bodies Home Can Impact Health

Five University at Buffalo research projects aim to study how the interplay of the human microbiome – the collection of microorganisms that reside in and on the human body – and the environment affect a person’s risk for certain diseases.

– University at Buffalo


Radiology Trailblazers Named Leadership Luminaries

The Radiology Leadership Institute® (RLI) named E. Stephen Amis Jr., MD, FACR, and Glendon G. Cox, MD, as this year’s Leadership Luminary Award recipients for their exceptional service to the medical specialty.

– American College of Radiology (ACR)


Cancer Research Institute to Honor Three Scientists for Outstanding Contributions to Cancer Immunotherapy Research

Announcement of winners of the 2016 William B. Coley and Frederick W. Alt Awards, celebrating key scientific contributions to the fields of immunology, tumor immunology (also known as immuno-oncology), and cancer immunotherapy.

– Cancer Research Institute


NCCN Imaging Appropriate Use Criteria to Be Integrated Into National Decision Support Company’s CareSelect Imaging

Integration of NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™) into NDSC CareSelect Imaging will provide access to evidence-based imaging recommendations adapted from the NCCN Guidelines®.

– National Comprehensive Cancer Network® (NCCN®)


NantHealth and University of Utah Establish Heritage 1K Project to Discover Genetic Causes of 25 Rare and Common Diseases

NantHealth, Inc., (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, today announced that it has partnered with the University of Utah in analyzing the entire genomic profiles of at least 1,000 individuals who have a history of rare and life-threatening diseases and conditions in their respective families. The landmark project will focus on researching the genetic causes of 25 conditions, including, breast, colon, ovarian, and prostate cancers, amyotrophic lateral sclerosis (ALS), chronic lymphocytic leukemia, autism, preterm birth, epilepsy, and other hereditary conditions. Genomic sequencing will be conducted with unique, comprehensive molecular tests offered by NantHealth.

– University of Utah Health Sciences


Marketplace


Advanced Instruments Introduces GloCyte® Automated Cell Counter for CSF

Advanced Instruments, Inc., a leader in laboratory instrumentation, launches their GloCyte Automated Cell Counter System at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo in Philadelphia, PA July 31–August 4. This new fluorescence and microscopy technology recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and marks a major achievement in giving laboratories a new way to obtain reliable and timely CSF results, especially at the more challenging low end counts.

– 2016 AACC Annual Meeting Press Program


Roche Receives FDA Approval for Novel PD-L1 Biomarker Assay

Roche today announced approval of the VENTANA PD-L1 (SP142) Assay1 by the US Food and Drug Administration (FDA) as a complementary diagnostic to provide PD-L1 status on patients who are considering treatment with the FDA approved Roche immunotherapy TECENTRIQ™ (atezolizumab) for metastatic urothelial cancer (mUC). This test is the first to evaluate patient PD-L1 status using immune cell staining and scoring within the tumor microenvironment, providing clinicians with information that may guide immunotherapy decisions2.

– 2016 AACC Annual Meeting Press Program

Tips

CUSTOMIZE YOUR FAVORITES WITH "MY READING LIST"

MY CHANNELS  |  SAVED ARTICLES  |  MY SOURCES  |  MY EXPERTS

MORE CHANNELS:
JOURNAL NEWS   |  TRENDS AND TOP STORIES   |  LOCAL NEWS  |  MEDICAL and SCIENTIFIC MEETINGS

Support
 Subscribe/Unsubscribe
 Edit My Preferences
 Comments/Suggestions
 Contact Us
 
Services
 Newswise Home
 Newswise Contact Directory
 Expert Queries
 Presspass Application

More News from:

  Newswise

 National Cancer Institute (NCI) at NIH

 University of Michigan Health System

 University of Wisconsin-Madison

 University of Texas M. D. Anderson Cancer Center

 UT Southwestern Medical Center

 University of California, Los Angeles (UCLA), Health Sciences

 George Washington University


Subscribe / Unsubscribe
Edit my preferences

© 2016 Newswise, Inc. All Rights Reserved.

215 E. 5th St. SW, Charlottesville VA 22903 | 434-296-9417

 Contact Us